Real world experiences: Pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis

Journal of Clinical Medicine

Volumn 5, Issue 9, 2016, Pages

  Hughes, Gareth ^a,b   Toellner, Hannah ^c   Morris, Helen ^a   Leonard, Colm ^a,b   Chaudhuri, Nazia ^a,b  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis; IPF; Nintedanib; Pirfenidone

Indexed keywords

ELECTROLYTE; NINTEDANIB; PIRFENIDONE; UREA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; BLOATING; BLOOD CELL COUNT; CHEST INFECTION; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEMOPTYSIS; HUMAN; LETHARGY; LOSS OF APPETITE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; RASH; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 85014767593     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5090078     Document Type: Review

References (20)

1. Ley, B.; Collard, H.R.; King, T.E. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2011, 183, 431-440. [CrossRef] [PubMed]
2. Raghu, G.; Rochwerg, B.; Zhang, Y.; Cuello Garcia, C.A.; Azuma, A.; Behr, J.; Brozek, J.L.; Collard, H.R.; Cunningham, W.; Homma, S.; et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015, 192, e3-e19. [CrossRef]
3. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis in adults: Diagnosis and management. In NICE Guideline (CG163); National Institute for Health and Care Excellence: Manchester, UK, 2013.
4. National Institute for Health and Care Excellence. Pirfenidone for treating idiopathic pulmonary fibrosis. In NICE Technology Appraisal Guidance (TA282); National Institute for Health and Care Excellence: Manchester, UK, 2013.
5. National Institute for Health and Care Excellence. Nintedanib for treating idiopathic pulmonary fibrosis. In NICE Technology Appraisal Guidance (TA379); National Institute for Health and Care Excellence: Manchester, UK, 2016.
6. Noble, P.W.; Albera, C.; Bradford, W.Z.; Costabel, U.; Glassberg, M.K.; Kardatzke, D.; King, T.E., Jr.; Lancaster, L.; Sahn, S.A.; Szwarcberg, J.; et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011, 377, 1760-1769. [CrossRef]
7. King, T.E.; Bradford,W.Z.; Castro-Bernardini, S. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2014, 370, 2083-2092. [CrossRef] [PubMed]
8. Coward,W.R.; Saini, G.; Jenkins, G. The pathogenesis of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis.2010, 4, 367-388. [CrossRef] [PubMed]
9. Richeldi, L.; Costabel, U.; Selman, M.; Kim, D.S.; Hansell, D.M.; Nicholson, A.G.; Brown, K.K.; Flaherty, K.R.; Noble, P.W.; Raghu, G.; et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011, 365, 1079-1087. [CrossRef]
10. Richeldi, L.; du Bois, R.M.; Raghu, G.; Azuma, A.; Brown, K.K.; Costabel, U.; Cottin, V.; Flaherty, K.R.; Hansell, D.M.; Inoue, Y.; et al. Efficacy and Safety of Nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014, 370, 2071-2082. [CrossRef]
11. Chaudhuri, N.; Duck, A.; Frank, R.; Holme, J.; Leonard, C. Real world experiences: Pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir. Med. 2014, 108, 224-226. [CrossRef] [PubMed]
12. Wijsenbeek, M.S.; Grutters, J.C.;Wuyts,W.A. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: A Retrospective Cohort Analysis. Adv. Ther. 2015, 32, 691-704. [CrossRef]
13. Costabel, U.; Albera, C.; Bradford, W.Z.; Hormel, P.; King, T.E., Jr.; Noble, P.W.; Sahn, S.A.; Valeyre, D.; du Bois, R.M. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffus. Lung Dis. 2014, 31, 198-205.
14. The British Thoracic Society Interstitial Lung Disease Registry Programme Annual Report 2014/15. British Thoracic Society Reports. 2015, Volume 7. Available online: https://www.brit-thoracic.org.uk/documentlibrary/ audit-and-quality-improvement/lung-disease-registry/bts-ild-registry-programme-annualreport-201415/ (accessed on 6 July 2016).
15. Costabel, U.; Bendstrup, E.; Cottin, V.; Dewint, P.; Egan, J.J.; Ferguson, J.; Groves, R. Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events. Adv. Ther.2014, 31, 375-391. [CrossRef] [PubMed]
16. Cottin, V.; Crestani, B.; Valeyre, D.; Wallaert, B.; Cadranel, J.; Dalphin, J.C.; Delaval, P.; Israel-Biet, D.; Kessler, R.; Reynaud-Gaubert, M.; et al. Diagnosis and Management of Idiopathic Pulmonary Fibrosis: French practical guidelines. Eur. Respir. Rev. 2014, 23, 193-214. [CrossRef] [PubMed]
17. Edwards, R.; Alonson, J.K. Adverse drug reactions, definitions, diagnosis and management. Lancet 2000, 356, 1255-1259. [CrossRef]
18. Mazzei, M.E.; Richeldi, L.; Callard, H.R. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 2015, 9, 121-129. [CrossRef] [PubMed]
19. Drucker, A.M.; Rosen, C.F. Drug-Induced Photosensitivity, Culprit drugs, management and prevention. Drug Saf. 2011, 34, 821-837. [CrossRef] [PubMed]
20. Valeyre, D.; Albera, C.; Bradford, W.Z.; Costabel, U.; King, T.E., Jr.; Leff, J.A.; Noble, P.W.; Sahn, S.A.; du Bois, R.M. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014, 19, 740-747. [CrossRef] [PubMed]